BF Biosciences introduces Sibionics CGM devices in Pakistan

BF Biosciences Limited (PSX: BFBIO) has launched Continuous Glucose Monitoring (CGM) devices in Pakistan together with China-based SIBIONICS, according to Mettis Global. The devices will carry the Sibionics CGM brand name in the local market. Founded in 2015, the Chinese partner has built a presence in over 100 countries and serves more than 4 million users.

CGM is an emerging tool for diabetes care that tracks glucose levels and their trends on a continuous basis. It shows patients and healthcare professionals how food, physical activity and other lifestyle factors influence glucose patterns. Mettis Global added that such data can help users make better-informed choices on diabetes and lifestyle.

BF Biosciences says the device is meant to complement its current metabolic range, which includes Ferulin (Insulin), Sematide (Semaglutide) and Zeptide (Tirzepatide), used where clinically suitable, with guidance from healthcare professionals. The company also plans to pair the devices with medicines and disease-awareness efforts such as SlimPossible, aiming for a wider strategy covering diabetes, obesity and linked metabolic disorders. It has committed to updating shareholders and the exchange on material developments, and the information was filed through a notice to the exchange.